NRIXNurix Therapeutics, Inc.
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics with a Buy and raises the price target from $34 to $36. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics with a Outperform and lowers the price target from $36 to $35. ...
- Analyst Upgrades
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32
Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics with a Outperform and raises the price target from $28 to $32. ...
- Analyst Upgrades
Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics with a Buy and lowers the price target from $34 to $33. ...
- Analyst Upgrades
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
Baird analyst Joel Beatty maintains Nurix Therapeutics with a Outperform and raises the price target from $33 to $36. ...
- Analyst Upgrades
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics with a Buy and maintains $34 price target. ...
- GlobeNewswire
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting ...
- GlobeNewswire
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg ...
- GlobeNewswire
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein ...
- GlobeNewswire
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics with a Outperform and raises the price target from $33 to $36. ...
- Analyst Upgrades
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics with a Buy and maintains $34 price target. ...
- GlobeNewswire
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive ...
- GlobeNewswire
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating ...
- Analyst Upgrades
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38
Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics with a Overweight and raises the price target from $36 to $38. ...
- Analyst Upgrades
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31
UBS analyst David Dai maintains Nurix Therapeutics with a Buy and raises the price target from $23 to $31. ...
- GlobeNewswire
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein ...
- Analyst Upgrades
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34
Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics with a Outperform and raises the price target from $30 to $34. ...
- Analyst Upgrades
Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics with a Buy and raises the price target from $32 to $34. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics with a Outperform and raises the price target from $30 to $33. ...
- Analyst Upgrades
Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40
Stifel analyst Stephen Willey maintains Nurix Therapeutics with a Buy and raises the price target from $34 to $40. ...
- Analyst Upgrades
BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics with a Buy and maintains $32 price target. ...
- Analyst Upgrades
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics with a Buy and maintains $34 price target. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics with a Buy and raises the price target from $32 to $34. ...
- Analyst Upgrades
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33
Baird analyst Joel Beatty maintains Nurix Therapeutics with a Outperform and raises the price target from $26 to $33. ...